卡铂加入序贯紫杉-蒽环新辅助化疗治疗三阴性乳腺癌:III期随机对照试验
这项III期随机对照试验评估在标准紫杉-蒽环新辅助化疗基础上加入卡铂对三阴性乳腺癌生存的影响。获益仅限于绝经前患者,交互作用显著。
要点
- 绝经前患者EFS和OS均显著获益(HR 0.61和0.57),绝经后无显著差异。
- 卡铂组3级及以上骨髓抑制更多,非血液学毒性无差异。
核心结论
- 卡铂未显著增加EFS但显著增加OS,获益仅限于绝经前患者。
研究设计与样本
- III期随机对照试验,2010年4月至2020年1月随机分配720例TNBC患者,717例纳入改良意向治疗分析(卡铂组361例,对照组356例)。
- 分层因素为分期和绝经状态,试验组接受每周卡铂(AUC-2)联合紫杉醇(100 mg/m2)8周,序贯4周期蒽环联合环磷酰胺,对照组为相同化疗但不加卡铂。
- 主要终点为EFS,次要终点为OS和病理完全缓解。
主要发现
- 研究干预与绝经状态对EFS和OS存在统计学显著交互作用,绝经前患者从卡铂获益而绝经后无获益。
临床怎么用
- 对于绝经前三阴性乳腺癌患者,可考虑在紫杉-蒽环新辅助化疗基础上加入卡铂以改善生存。
- 绝经后患者加用卡铂未显示生存获益,需个体化决策并关注骨髓抑制风险。
局限性
- 绝经状态亚组分析为名义P值,需谨慎解读。
- OS结果仅为名义P值,非预设主要终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m2) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.
引用
- Gupta S, Nair N, Hawaldar RW, et al. Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2025. PMID: 41115255. doi:10.1200/JCO-25-01023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。